Colorectal cancer (CRC) is a major cause of mortality in western society with a 5-year survival of approximately 50%. Metastasis to the liver and lungs is the principal cause of death and occurs in up to 25% of patients at presentation. Despite advances in available techniques for treating metastases, the majority of patients remain incurable and existing adjuvant therapies such as chemotherapy are only of limited effectiveness. Understanding the molecular mechanisms underlying the metastatic process may allow us to identify those at greatest risk of recurrence and discover new tumour targets to prevent disease progression. It is now apparent that tumour stroma plays an important role in promoting tumour progression. A pronounced desmoplastic reaction was associated with a reduced immune response and has been shown to be an independent poor prognostic indicator in CRC and cancer recurrence. Determining the cause(s) and effect(s) of this stromal response will further our understanding of tumour cell/stromal interactions, and will help us identify prognostic indicators for patients with CRC. This will not only allow us to target our existing treatments more effectively, we also aim to identify novel and more specific therapeutic targets for the treatment of CRC which will add to our current therapeutic options.
References
[1]
Office for National Statistics. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2007; Series MB1 No. 38; England, 2010.
[2]
Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867.
Liotta, L.A.; Kohn, E.C. The microenvironment of the tumour-host interface. Nature 2001, 411, 375–379.
[5]
De Wever, O.; Demetter, P.; Mareel, M.; Bracke, M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123, 2229–2238.
[6]
Tsujino, T.; Seshimo, I.; Yamamoto, H.; Ngan, C.Y.; Ezumi, K.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; Matsuura, N.; Monden, M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 2007, 13, 2082–2090.
[7]
Kellermann, M.G.; Sobral, L.M.; da Silva, S.D.; Zecchin, K.G.; Graner, E.; Lopes, M.A.; Nishimoto, I.; Kowalski, L.P.; Coletta, R.D. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology 2007, 51, 849–853.
[8]
Surowiak, P.; Murawa, D.; Materna, V.; Maciejczyk, A.; Pudelko, M.; Ciesla, S.; Breborowicz, J.; Murawa, P.; Zabel, M.; Dietel, M.; et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 2007, 27, 2917–2924.
De Wever, O.; Nguyen, Q.D.; Van Hoorde, L.; Bracke, M.; Bruyneel, E.; Gespach, C.; Mareel, M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004, 18, 1016–1018.
[11]
Andersson-Sj？land, A.; de Alba, C.G.; Nihlberg, K.; Becerril, C.; Ramírez, R.; Pardo, A.; Westergren-Thorsson, G.; Selman, M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008, 40, 2129–2140.
[12]
Saigusa, S.; Toiyama, Y.; Tanaka, K.; Yokoe, T.; Okugawa, Y.; Kawamoto, A.; Yasuda, H.; Inoue, Y.; Miki, C.; Kusunoki, M. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann. Surg. Oncol. 2010, 17, 2051–2058.
[13]
Radisky, D.C.; Kenny, P.A.; Bissell, M.J. Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT? J. Cell. Biochem. 2007, 101, 830–839.
[14]
Xu, J.; Lamouille, S.; Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172.
[15]
Van Zijl, F.; Mair, M.; Csiszar, A.; Schneller, D.; Zulehner, G.; Huber, H.; Eferl, R.; Beug, H.; Dolznig, H.; Mikulits, W. Hepatic tumor-stroma cross-talk guides epithelial to mesenchymal transition at the tumour edge. Oncogene 2009, 28, 4022–4033.
[16]
Wakefield, L.M.; Roberts, A.B. TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 2002, 12, 22–29.
[17]
Sheppard, D. Transforming growth factor beta: A central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 2006, 3, 413–417.
[18]
Safina, A.F.; Varga, A.E.; Bianchi, A.; Zheng, Q.; Kunnev, D.; Liang., P.; Bakin, A.V. Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion. Cell Cycle 2009, 8, 284–298.
Pino, M.S.; Kikuchi, H.; Zeng, M.; Herraiz, M.T.; Sperduti, I.; Berger, D.; Park, D.Y.; Iafrate, A.J.; Zukerberg, L.R.; Chung, D.C. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010, 138, 1406–1417.
[21]
Kirkland, S.C. Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br. J. Cancer 2010, 101, 320–326.
[22]
Bates, R.C.; Bellovin, D.I.; Brown, C.; Maynard, E.; Wu, B.; Kawakatsu, H.; Sheppard, D.; Oettgen, P.; Mercurio, A.M. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 2005, 115, 339–347.
[23]
Serini, G.; Bochaton-Piallat, M.L.; Ropraz, P.; Geinoz, A.; Borsi, L.; Zardi, L.; Gabbiani, G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J. Cell. Biol. 1998, 10, 873–881.
[24]
Lenga, Y.; Koh, A.; Perera, A.S.; McCulloch, C.A.; Sodek, J.; Zohar, R. Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 2008, 102, 319–327.
Imano, M.; Okuno, K.; Itoh, T.; Ishimaru, E.; Satou, T.; Shiozaki, H. Increased osteopontin positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis. World J. Surg. 2010, 34, 1930–1936.
[27]
El Kahi, C.G.; Atiyeh, B.S.; Abdallah, H.; Hussein, I.; Jurjus, R.; Dibo, S.A.; Jurjus, A.; Jurjus, A. Modulation of wound contracture alpha-smooth muscle actin and multispecific vitronectin receptor integrin alphavbeta3 in the rabbit's experimental model. Int. Wound J. 2009, 6, 214–224.
[28]
Ding, Q.; Gladson, C.L.; Wu, H.; Hayasaka, H.; Olman, M.A. Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J. Biol. Chem. 2008, 283, 26839–26849.
[29]
Lygoe, K.A.; Wall, I.; Stephens, P.; Lewis, M.P. Role of vitronectin and fibronectin receptors in oral mucosal and dermal myofibroblast differentiation. Biol. Cell 2007, 99, 601–614.
[30]
Yamasaki, M.; Kang, H.R.; Homer, R.J.; Chapoval, S.P.; Cho, S.J.; Lee, B.J.; Elias, J.A.; Lee, C.G. P21 regulates TGF-beta1-induced pulmonary responses via a TNF-alpha-signaling pathway. Am. J. Respir. Cell Mol. Biol. 2008, 38, 346–353.
[31]
Webber, J.; Jenkins, R.H.; Meran, S.; Phillips, A.; Steadman, R. Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan. Am. J. Pathol. 2009, 175, 148–160.
[32]
Bharadwaj, A.G.; Kovar, J.L.; Loughman, E.; Elowsky, C.; Oakley, G.G.; Simpson, M.A. Spontaneous metastasis of prostate cancer is promoted by excess hyaluornan synthesis and processing. Am. J. Path. 2009, 174, 1027–1036.
[33]
Lugli, A.; Zlobec, I.; Günthert, U.; Minoo, P.; Baker, K.; Tornillo, L.; Terracciano, L.; Jass, J.R. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Modern Pathol. 2006, 19, 1302–1309.
[34]
Surowiak, P.; Murawa, D.; Materna, V.; Maciejczyk, A.; Pudelko, M.; Ciesla, S.; Breborowicz, J.; Murawa, P.; Zabel, M.; Dietel, M.; et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 2007, 27, 2917–2924.
[35]
Marsh, D.; Suchak, K.; Moutasim, K.A.; Vallath, S.; Hopper, C.; Jerjes, W.; Upile, T.; Kalavrezos, N.; Violette, S.M.; Weinreb, P.H.; et al. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 2011, 223, 470–481.
[36]
Li, F.Y.; Lai, M.D. Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B 2009, 10, 219–229.
[37]
Ueno, H.; Jones, A.M.; Wilkinson, K.H.; Jass, J.R.; Talbot, I.C. Histological categoristaion of fibrotic cancer stroma in advanced rectal cancer. Gut 2004, 53, 581–586.
[38]
Cui, G.; Yuan, A.; Vonen, B.; Florholmen, J. Progressive cellular response in the lamina propria of the colorectal adenoma—Carcinoma sequence. Histopathology 2009, 54, 550–560.
[39]
Marsh, D.; Dickinson, S.; Neill, G.W.; Marshall, J.F.; Hart, I.R.; Thomas, G.J. αvβ6 integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res. 2008, 68, 3295–3303.
[40]
Svagzyds, S.; Lesauskaite, V.; Pangonyte, D.; Saladzinskas, Z.; Tamelis, A.; Pavalkis, D. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. Tohoku J. Exp. Med. 2011, 223, 67–73.
[41]
Gaggioli, C.; Hooper, S.; Hidalgo-Carcedo, C.; Grosse, R.; Marshall, J.F.; Harrington, K.; Sahai, E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell. Biol. 2007, 9, 1392–1400.
[42]
Sis, B.; Sarioglu, S.; Sokmen, S.; Sakar, M.; Kupelioglu, A.; Fuzun, M. Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma. J. Clin. Path. 2005, 58, 32–38.
[43]
Crispino, P.; De Toma, G.; Ciardi, A.; Bella, A.; Rivera, M.; Cavallaro, G.; Polistena, A; Fornari, F.; Unim, H.; Pica, R.; et al. Role of desmoplasia in recurrence of stage II colorectal cancer within 5 years after surgery and therapeutic implication. Cancer Invest. 2008, 26, 419–425.
[44]
Yoong, K.F.; Afford, S.C.; Randhawa, S.; Hubscher, S.G.; Adams, D.H. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 1999, 154, 693–703.
[45]
Conti, J.A.; Kendall, T.J.; Bateman, A.; Armstrong, T.A.; Papa-Adams, A.; Xu, Q.; Packham, G.; Primrose, J.N.; Benyon, R.C.; Iredale, J.P. The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation. Clin. Cancer Res. 2008, 14, 6405–6413.
[46]
Monnier, Y.; Farmer, P.; Bieler, G.; Imaizumi, N.; Sengstag, T.; Alghisi, G.C.; Stehle, J.C.; Ciarloni, L.; Andrejevic-Blant, S.; Moeckli, R.; et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in pre-irradiated stroma. Cancer Res. 2008, 68, 7323–7331.
[47]
Yang, G.Y.; Xu, K.S.; Pan, Z.Q.; Zhang, Z.Y.; Mi, Y.T.; Wang, J.S.; Chen, R.; Niu, J. Integrin alphavbeta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 2008, 99, 879–887.
[48]
He, J.M.; Wang, F.C.; Qi, H.B.; Li, Y.; Liang, H.J. Down-regulation of alphav integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29. Cancer Lett. 2009, 284, 182–188.
[49]
Vermeulen, L.; De Sousa, E.; Melo, F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell. Biol. 2010, 12, 468–476.
[50]
Cui, G.; Goll, R.; Olsen, T.; Steigen, S.E.; Husebekk, A.; Vonen, B.; Florholmen, J. Reduced expression of microenvironment Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol. Immunother. 2007, 56, 985–995.
[51]
Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pagès, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960–1964.
[52]
Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909–915.
